247 related articles for article (PubMed ID: 20586517)
21. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
22. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
23. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
24. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
Matuszkiewicz-Rowińska J; Żebrowski P
Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
[TBL] [Abstract][Full Text] [Related]
25. Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease.
Sözel H; Köksoy S; Ozdem S; Yılmaz F; Bora F; Ersoy FF
Int Urol Nephrol; 2020 Aug; 52(8):1563-1570. PubMed ID: 32405698
[TBL] [Abstract][Full Text] [Related]
26. The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
Egido J; Martínez-Castelao A; Bover J; Praga M; Torregrosa JV; Fernández-Giráldez E; Solozábal C
Nefrologia; 2016; 36(1):10-8. PubMed ID: 26705959
[TBL] [Abstract][Full Text] [Related]
27. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Andress D
Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.
Han T; Rong G; Quan D; Shu Y; Liang Z; She N; Liu M; Yang B; Cheng G; Lv Y; Stern L
Biomed Res Int; 2013; 2013():320560. PubMed ID: 23509710
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
Ritchie M; Liedgens H; Nuijten M
Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
[TBL] [Abstract][Full Text] [Related]
30. Paricalcitol for secondary hyperparathyroidism in renal transplantation.
Trillini M; Cortinovis M; Ruggenenti P; Reyes Loaeza J; Courville K; Ferrer-Siles C; Prandini S; Gaspari F; Cannata A; Villa A; Perna A; Gotti E; Caruso MR; Martinetti D; Remuzzi G; Perico N
J Am Soc Nephrol; 2015 May; 26(5):1205-14. PubMed ID: 25194004
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
32. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Fiedler R
Clin Drug Investig; 2007; 27(12):865-6. PubMed ID: 18020546
[No Abstract] [Full Text] [Related]
33. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud H; Coyne D; Smolenski O; Anger M; Lunde N; Qiu P; Hippensteel R; Pradhan RS; Palaparthy RV; Kavanaugh A; Melnick JZ; Williams LA; Batlle D
Am J Nephrol; 2006; 26(1):105-14. PubMed ID: 16543714
[TBL] [Abstract][Full Text] [Related]
34. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
[TBL] [Abstract][Full Text] [Related]
35. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis.
Cheng J; Zhang W; Zhang X; Li X; Chen J
Clin J Am Soc Nephrol; 2012 Mar; 7(3):391-400. PubMed ID: 22223607
[TBL] [Abstract][Full Text] [Related]
37. Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism.
Giakoumis M; Tsioufis C; Dimitriadis K; Sonikian M; Kasiakogias A; Andrikou E; Kalos T; Konstantinidis D; Filis K; Petras D; Tousoulis D
Hellenic J Cardiol; 2019; 60(2):108-113. PubMed ID: 29305902
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
Donate-Correa J; Domínguez-Pimentel V; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
Curr Drug Targets; 2014; 15(7):703-9. PubMed ID: 24745821
[TBL] [Abstract][Full Text] [Related]
39. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
40. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.
Brancaccio D; Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M
Contrib Nephrol; 2009; 163():219-226. PubMed ID: 19494617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
